Stage II HR-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Njathi, Female, 40s | Stage II

Biomarkers: Triple-positive; ER-positive; PR-positive; HER2-positive

As of October 2025, Jennifer was more than 1 year past treatment for triple-positive Stage IIA breast cancer and had a recent clear MRI.

City of HopeRead more →

Deltra: Stage IV triple-negative breast cancer and sexual health advocacy story

Patient Info: Deltra, Female | Stage IV

Biomarkers: Triple-negative breast cancer

As of October 2025, Deltra was described as a mother of 5 living with triple-negative metastatic breast cancer and advocating for better sexual-health conversations in oncology care.

Stage II Triple-Negative Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Rancik, Female, Under 40 | Stage II

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Jennifer entered remission in October 2017 after Stage II triple-negative breast cancer treatment and, as of October 2025, reported doing great and being off medications except occasional Zometa.

City of HopeRead more →

Triple-negative metastatic breast cancer with pituitary metastasis: symptom relief after debulking

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Pituitary metastasis was triple-negative breast cancer with no HER2 amplification.

Metastatic Site: liver; bone/skull; right breast; left orbit/optic…

Transsphenoidal debulking relieved visual symptoms and 6-month MRI showed no pituitary recurrence, while known metastatic breast cancer at other sites remained part of her ongoing cancer course.

PubMed CentralRead more →

Stage IIIA triple-negative breast cancer with hypercalcemia from parathyroid adenoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

As of October 2025, evaluation for post-chemotherapy weakness showed no local breast cancer recurrence, no lymphadenopathy, and no bone metastases; hypercalcemia resolved after parathyroid adenoma removal while breast cancer care remained ongoing.

PubMed CentralRead more →

PT3N0 triple-negative breast carcinosarcoma: surgery, EC chemotherapy, radiation, disease-free at 26 months

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast carcinosarcoma. INI1 was retained

She was clinically free of disease at her last follow-up in April 2025, 26 months after treatment completion; December 2024 mammography showed no suspicious changes.

PubMed CentralRead more →

Paget disease, bilateral apocrine breast carcinomas, and primary breast follicular lymphoma after aromatase inhibition

Patient Info: Anonymized, Female, 70+

Biomarkers: Initial breast cancer was ER/PR-positive, HER2-negative. Later apocrine cancers were triple-negative with AR/ER-beta markers. Lymphoma had IgH::BCL2.

As of September 2025, she was alive 3 years after bilateral mastectomy and observation for Stage Ie follicular lymphoma, with no recurrence of either breast carcinoma or lymphoma.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Melissa's Patient Story

Patient Info: Melissa Fouts, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: Outside the lungs / pleural area

As of September 2025, Melissa had been on low-dose eribulin for almost 7 years; 6 metastatic nodules outside the lungs had shrunk and stabilized, with 3 nearly undetectable on scans.

MD AndersonRead more →

Triple-negative breast pleomorphic adenocarcinoma: disease-free after mastectomy and one course of capecitabine

Patient Info: Anonymized, Female, 70+

Biomarkers: Triple-negative breast pleomorphic adenocarcinoma with PIK3CA mutation; markers supported the diagnosis.

As of September 2025, she had 2 years of disease-free survival after left total mastectomy, sentinel lymph node exploration, and 1 course of oral capecitabine.

PubMed CentralRead more →

Triple-negative breast cancer history with later chest wall sarcomatoid carcinoma treated by embolization, ablation, and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Initial breast cancer was triple-negative. Later chest-wall lesion was weak ER-positive, PR/HER2-negative

By February 2025, the treated chest wall lesion had decreased to about 13 x 7 mm after embolization, radiofrequency ablation, and albumin-bound paclitaxel plus cisplatin, with no peripheral or distant metastatic foci seen.

PubMed CentralRead more →

Triple-negative node-positive breast cancer with complete pathologic response and benign nodal nevi

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer; BRCA testing negative. Axillary melanocytic cells looked benign.

Pathology showed complete response in the breast, no residual breast carcinoma in the sampled specimen, and axillary nodal melanocytic proliferations interpreted as benign nodal nevi rather than metastatic melanoma or breast carcinoma.

PubMed CentralRead more →

Synchronous triple-negative breast cancer and rectal adenocarcinoma complicated by hepatitis B reactivation

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer with pathogenic BRCA1 mutation; hepatitis B reactivation occurred during treatment.

At 3-year follow-up, she remained healthy and disease-free after treatment for synchronous triple-negative breast cancer and mid-rectal adenocarcinoma, with hepatitis B reactivation controlled on entecavir.

PubMed CentralRead more →

Rare Reversed-Polarity Breast Cancer in a 69-Year-Old Woman

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-negative, PR-negative, HER2-negative, IDH2 mutation, PIK3CA mutation, triple negative

Alive and disease-free 13 months after surgery.

PubMed CentralRead more →

Stage III Triple-Negative Breast Cancer: Paula's Survivor Story

Patient Info: Paula Jones, Female, 40s | Stage III

Biomarkers: Triple-negative breast cancer; BRCA1 mutation

As of July 2025, Paula had remained cancer-free for more than 15 years after Stage IIIC triple-negative breast cancer treatment and was training to become a mammography technologist.

MD AndersonRead more →

Stage III Triple-Negative Breast Cancer: Lynn's Survivor Story

Patient Info: Lynn Leiro, Female, Under 40 | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Lynn achieved complete response after breast cancer treatment and remission from therapy-related acute lymphocytic leukemia after CAR T cell therapy and bone marrow transplant; as of July 2025, nearly 1 year post-transplant, she was doing better and getting stronger.

City of HopeRead more →

Stage IIIB triple-negative breast cancer: complete response after LVAD-supported neoadjuvant immunotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 95%; nuclear grade 3, triple negative

As of July 2025, breast cancer remained in remission 2.5 years after mastectomy, after neoadjuvant paclitaxel/carboplatin/pembrolizumab, surgery, radiation, and 1 year of adjuvant pembrolizumab.

PubMed CentralRead more →

Stage 4 triple-negative breast cancer: NED after adrenalectomy

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; CA 15-3 elevated at recurrence; normalized post-surgery

Metastatic Site: adrenal gland

After adrenalectomy, serum CA15-3 and metanephrine/normetanephrine levels normalized, and the preoperative workup had found no other metastatic disease.

PubMed CentralRead more →

Triple-Negative Breast Cancer: LaToya's Survivor Story

Patient Info: LaToya Bolds-Johnson, Female

Biomarkers: Triple-negative breast cancer

As of June 2025, LaToya was described as a triple-negative breast cancer survivor, Physician Associate, and clinical-trials advocate; the record supports advocacy around trials, not that a trial was her own received treatment.

Melissa Eppard: Stage I triple-negative breast cancer survivorship and intimacy recovery story

Patient Info: Melissa Eppard, Female | Stage I

Biomarkers: Triple-negative breast cancer

As of June 2025, Melissa was described as a Stage I triple-negative breast cancer survivor, cancer thriver, coach, and co-founder focused on intimacy, comfort, confidence, and sexual wellness after cancer.

Triple-negative sebaceous carcinoma of the breast: no recurrence after multimodality treatment

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative sebaceous breast carcinoma; EMA-positive; Ki-67 50-60%; inherited breast/ovarian cancer testing negative for pathogenic variants.

As of May 2025, after surgery, adjuvant chemotherapy, and radiation, she had 5 years of follow-up with no evidence of neoplastic recurrence.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Lauren's Survivor Story

Patient Info: Lauren Yerkes, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

As of May 2025, Lauren Yerkes was a triple-negative breast cancer survivor and founder of POST SWIM, a swimwear brand created from her post-mastectomy experience.

Stage III HR-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-positive

Three years after diagnosis, Christine described herself in the survivorship stage and focused on the physical and emotional effects that continued after active treatment.

The Patient StoryRead more →

Early-stage triple-negative breast cancer with separate lung carcinoid and later CML

Patient Info: Anonymized, Female, 50s

Biomarkers: triple negative

As of May 2025, serial follow-up breast ultrasound examinations showed no evidence of breast cancer recurrence in either breast tissue or axillary lymph nodes.

PubMed CentralRead more →

Metaplastic triple-negative breast cancer: near-complete response to taxane/carboplatin before surgery

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2-negative; CA 15-3 elevated, triple negative

As of April 2025, imaging after taxane/carboplatin showed a near-complete morpho-metabolic response in the right breast and major reduction of axillary nodal disease, followed by surgery and adjuvant chemotherapy/radiotherapy.

PubMed CentralRead more →